Glucocorticoids increase interleukin-6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor

Hepatology

Volumn 55, Issue 1, 2012, Pages 256-266

  Dittrich, Anna ^a,b   Khouri, Christina ^b   Sackett, Sara Dutton ^c   Ehlting, Christian ^d   Böhmer, Oliver ^d   Albrecht, Ute ^d   Bode, Johannes G ^d   Trautwein, Christian ^c   Schaper, Fred ^a,b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; DEXAMETHASONE; FIBRINOGEN; GAMMA FIBRINOGEN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; MESSENGER RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOWN REGULATION; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MOTIF; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ACUTE-PHASE REACTION; ANIMALS; CELLS, CULTURED; DEXAMETHASONE; FEEDBACK, PHYSIOLOGICAL; GLUCOCORTICOIDS; HEP G2 CELLS; HEPATOCYTES; HUMANS; INTERLEUKIN-6; MICE; MICE, MUTANT STRAINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84155178400     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24655     Document Type: Article

References (34)

1. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426.
2. Stöcklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996; 383: 726-728.
3. Lechner J, Welte T, Tomasi JK, Bruno P, Cairns C, Gustafsson J, et al. Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of beta-casein gene transcription. J Biol Chem 1997; 272: 20954-20960.
4. Takeda T, Kurachi H, Yamamoto T, Nishio Y, Nakatsuji Y, Morishige K, et al. Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. J Endocrinol 1998; 159: 323-330.
5. Zhang ZX, Jones S, Hagood JS, Fuentes NL, Fuller GM. STAT3 acts as a co-activator of glucocorticoid receptor signaling. J Biol Chem 1997; 272: 30607-30610.
6. Lerner L, Henriksen MA, Zhang X, Darnell JE Jr. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev 2003; 17: 2564-2577.
7. Biola A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertoglio J, Pallardy M. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 2001; 15: 1062-1076.
8. Hu X, Li WP, Meng C, Ivashkiv LB. Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol 2003; 170: 4833-4839.
9. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002; 22: 7802-7811.
10. Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi TA, Decker K, et al. Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem 1988; 173: 287-293.
11. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Muller M, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010; 207: 1453-1464.
12. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 receptor components. Science 1994; 263: 92-95.
13. Lütticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, et al. Association of transcription factor APRF and protein kinase Jak 1 with the interleukin-6 signal transducer gp 130. Science 1994; 263: 89-92.
14. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-921.
15. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929.
16. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-924.
17. Fischer P, Lehmann U, Sobota RM, Schmitz J, Niemand C, Linnemann S, et al. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J 2004; 378: 449-460.
18. Yang XP, Schaper F, Teubner A, Lammert F, Heinrich PC, Matern S, et al. Interleukin-6 plays a crucial role in the hepatic expression of SOCS3 during acute inflammatory processes in vivo. J Hepatol 2005; 43: 704-710.
19. Ehlting C, Lai WS, Schaper F, Brenndörfer ED, Matthes RJ, Heinrich PC, et al. Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. J Immunol 2007; 178: 2813-2826.
20. Yang XP, Albrecht U, Zakowski V, Sobota RM, Haussinger D, Heinrich PC, et al. Dual function of interleukin-1beta for the regulation of interleukin-6-induced suppressor of cytokine signaling 3 expression. J Biol Chem 2004; 279: 45279-45289.
21. Siewert E, Müller-Esterl W, Starr R, Heinrich PC, Schaper F. Different protein turnover of interleukin-6-type cytokine signalling components. Eur J Biochem 1999; 265: 251-257.
22. Baumann H, Richards C, Gauldie J. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol 1987; 139: 4122-4128.
23. Baumann H, Jahreis GP, Morella KK. Interaction of cytokine- and glucocorticoid-response elements of acute-phase plasma protein genes. Importance of glucocorticoid receptor level and cell type for regulation of the elements from rat alpha 1-acid glycoprotein and beta-fibrinogen genes. J Biol Chem 1990; 265: 22275-22281.
24. Plum W, Tschaharganeh DF, Kroy DC, Corsten E, Erschfeld S, Dierssen U, et al. Lack of glycoprotein 130/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis. Am J Pathol 2010; 176: 2236-2246.
25. Pfaffl MW, Nucl Acid Res 2001; 29: 2002-2007.
26. Schaper F, Gendo C, Eck M, Schmitz J, Grimm C, Anhuf D, et al. Activation of the protein tyrosine phophatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires JAK1 and limits acute-phase protein expression. Biochem J 1998; 335: 557-565.
27. Anhuf D, Weissenbach M, Schmitz J, Sobota R, Hermanns HM, Radtke S, et al. Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation. J Immunol 2000; 165: 2535-2543.
28. Schmitz J, Dahmen H, Grimm C, Gendo C, Müller-Newen G, Heinrich PC, et al. The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction. J Immunol 2000; 164: 848-854.
29. Radtke S, Wüller S, Yang XP, Lippok BE, Mütze B, Mais C, et al. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci 2010; 123: 947-959.
30. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 2000; 275: 12848-12856.
31. Paysant J, Blanque R, Vasse M, Soria C, Soria J, Gardner CR. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. Cytokine 2000; 12: 774-779.
32. Schooltink H, Stoyan T, Lenz D, Schmitz H, Hirano T, Kishimoto T, et al. Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J 1991; 277: 659-664.
33. Paul C, Seiliez I, Thissen JP, Le Cam A. Regulation of expression of the rat SOCS-3 gene in hepatocytes by growth hormone, interleukin-6 and glucocorticoids mRNA analysis and promoter characterization. Eur J Biochem 2000; 267: 5849-5857.
34. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003; 4: 551-556.